Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.

Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL.

J Immunol. 2014 Jul 15;193(2):783-96. doi: 10.4049/jimmunol.1302563. Epub 2014 Jun 13.

2.

Specifically binding of L-ficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation.

Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang X.

Cell Mol Immunol. 2009 Aug;6(4):235-44. doi: 10.1038/cmi.2009.32.

3.

Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.

Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J.

J Virol. 2014 Feb;88(3):1725-39. doi: 10.1128/JVI.02017-13. Epub 2013 Nov 20.

4.

Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese MT, Zeisel MB, Nicosia A, Baumert TF, Kaderali L, Pietschmann T.

J Virol. 2014 Nov;88(21):12644-55. doi: 10.1128/JVI.01145-14. Epub 2014 Aug 20.

5.

Role of N-linked glycans in the interactions of recombinant HCV envelope glycoproteins with cellular receptors.

Chen PC, Chuang PK, Chen CH, Chan YT, Chen JR, Lin SW, Ma C, Hsu TL, Wong CH.

ACS Chem Biol. 2014 Jul 18;9(7):1437-43. doi: 10.1021/cb500121c. Epub 2014 May 15.

PMID:
24766301
6.

Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.

Douam F, Dao Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D.

Hepatology. 2014 Mar;59(3):776-88. doi: 10.1002/hep.26733. Epub 2014 Jan 28.

PMID:
24038151
7.

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J.

J Virol. 2014 Sep;88(18):10584-97. doi: 10.1128/JVI.01402-14. Epub 2014 Jul 2.

8.

Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.

Dao Thi VL, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M.

J Biol Chem. 2012 Sep 7;287(37):31242-57. doi: 10.1074/jbc.M112.365924. Epub 2012 Jul 5.

9.

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL.

J Biol Chem. 2003 Oct 24;278(43):41624-30. Epub 2003 Aug 11.

10.

Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms.

Hishiki T, Shimizu Y, Tobita R, Sugiyama K, Ogawa K, Funami K, Ohsaki Y, Fujimoto T, Takaku H, Wakita T, Baumert TF, Miyanari Y, Shimotohno K.

J Virol. 2010 Nov;84(22):12048-57. doi: 10.1128/JVI.01063-10. Epub 2010 Sep 8.

11.

Recombinant human L-ficolin directly neutralizes hepatitis C virus entry.

Hamed MR, Brown RJ, Zothner C, Urbanowicz RA, Mason CP, Krarup A, McClure CP, Irving WL, Ball JK, Harris M, Hickling TP, Tarr AW.

J Innate Immun. 2014;6(5):676-84. doi: 10.1159/000362209. Epub 2014 May 15.

12.

Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry.

Qin ZL, Ju HP, Gao TT, Wang WB, Ren H, Zhao P, Qi ZT.

J Gen Virol. 2015 Jun;96(Pt 6):1389-99. doi: 10.1099/vir.0.000091. Epub 2015 Feb 20.

PMID:
25701820
13.

A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.

Harman C, Zhong L, Ma L, Liu P, Deng L, Zhao Z, Yan H, Struble E, Virata-Theimer ML, Zhang P.

J Virol. 2015 Jan;89(1):492-501. doi: 10.1128/JVI.01661-14. Epub 2014 Oct 22.

14.

Phospholipid scramblase 1 mediates hepatitis C virus entry into host cells.

Gong Q, Cheng M, Chen H, Liu X, Si Y, Yang Y, Yuan Y, Jin C, Yang W, He F, Wang J.

FEBS Lett. 2011 Sep 2;585(17):2647-52. doi: 10.1016/j.febslet.2011.07.019. Epub 2011 Jul 28.

15.

Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.

Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, Hua X, Chen Z, Ding H, Gao L, Wang Y, Feitelson MA, Zhao P, Qi ZT.

J Virol. 2011 Mar;85(6):2793-802. doi: 10.1128/JVI.01818-10. Epub 2010 Dec 22.

16.

Tandem overexpression of five human factors renders murine hepatocytes susceptible to hepatitis C virus.

Lv L, Kang Q, Yu X, Gao B, Hu T, Ma P, Zhang Y, Yan F, Xiao J, Deng J, Zhou X, Xu J.

Acta Virol. 2015 Mar;59(1):20-6.

PMID:
25790047
17.

Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.

Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Behrendt P, Brown RJ, Ciesek S, Wedemeyer H, Sarrazin C, Kaderali L, Pietschmann T, Steinmann E.

Hepatology. 2014 Aug;60(2):508-20. doi: 10.1002/hep.27190. Epub 2014 Jun 24.

PMID:
24771613
18.

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.

J Biol Chem. 2006 Jul 7;281(27):18285-95. Epub 2006 May 4.

19.

Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.

Wünschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT.

J Virol. 2000 Nov;74(21):10055-62.

20.

Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells.

Park GB, Kim D, Park SJ, Lee HK, Kim JH, Kim YS, Park SG, Choi IH, Yoon SH, Lee YJ, Paeng S, Hur DY.

Int J Mol Med. 2015 Dec;36(6):1464-78. doi: 10.3892/ijmm.2015.2372. Epub 2015 Oct 13.

Supplemental Content

Support Center